generic names for glp-1 drugs There's still no Ozempic, but a lower-priced daily injected is coming Understanding the health equity barriers

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Remember when I mentioned that these GLP1-RA medications are engineered to remain active in the body for much longer, providing sustained benefits

Biochemical and Biophysical Research Communications

Employers should continually reevaluate benefit design and programs for metabolic disease to keep their plans affordable and obtain maximum value for their members

132,133 A recent in vitro DDI study of ATSP-7041, a stapled -helical peptide being developed as an anticancer agent, revealed minimal CYP inhibition

Pederson RA, Brown JC